Terns Pharmaceuticals Stock Analysis
TERN Stock | USD 3.32 0.19 5.41% |
Terns Pharmaceuticals is undervalued with Real Value of 7.24 and Target Price of 19.06. The main objective of Terns Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Terns Pharmaceuticals is worth, separate from its market price. There are two main types of Terns Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Terns Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Terns Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Terns Stock trading window is adjusted to America/New York timezone.
Terns |
Terns Stock Analysis Notes
About 100.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.89. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Terns Pharmaceuticals recorded a loss per share of 1.12. The entity had not issued any dividends in recent years. The firm had 1000:50 split on the 4th of November 2013. Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. Terns Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. To find out more about Terns Pharmaceuticals contact Senthil Sundaram at 650 525 5535 or learn more at https://www.ternspharma.com.Terns Pharmaceuticals Investment Alerts
Terns Pharmaceuticals generated a negative expected return over the last 90 days | |
Terns Pharmaceuticals has high historical volatility and very poor performance | |
Terns Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
Net Loss for the year was (88.85 M) with profit before overhead, payroll, taxes, and interest of 1000 K. | |
Terns Pharmaceuticals currently holds about 139.81 M in cash with (70.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.51, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Terns Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
Over 100.0% of the company shares are owned by institutional investors | |
Latest headline from gurufocus.com: Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate ... |
Terns Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Terns Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
25th of March 2024 Upcoming Quarterly Report | View | |
20th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
25th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Terns Largest EPS Surprises
Earnings surprises can significantly impact Terns Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-11-12 | 2024-09-30 | -0.32 | -0.28 | 0.04 | 12 | ||
2024-05-13 | 2024-03-31 | -0.34 | -0.3 | 0.04 | 11 | ||
2023-05-15 | 2023-03-31 | -0.27 | -0.31 | -0.04 | 14 |
Terns Pharmaceuticals Environmental, Social, and Governance (ESG) Scores
Terns Pharmaceuticals' ESG score is a quantitative measure that evaluates Terns Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Terns Pharmaceuticals' operations that may have significant financial implications and affect Terns Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.
Terns Pharmaceuticals Thematic Classifications
In addition to having Terns Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
![]() | Israel Wall StreetLarge Israel companies traded on major USA exchanges |
Terns Stock Institutional Investors
Shares | Superstring Capital Management Lp | 2024-12-31 | 2 M | Driehaus Capital Management Llc | 2024-12-31 | 1.7 M | Millennium Management Llc | 2024-12-31 | 1.6 M | Geode Capital Management, Llc | 2024-12-31 | 1.5 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 1.5 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.3 M | State Street Corp | 2024-12-31 | 1.3 M | Point72 Asset Management, L.p. | 2024-12-31 | 1.3 M | Vr Adviser, Llc | 2024-12-31 | 1.1 M | Soleus Capital Management, L.p. | 2024-12-31 | 8.1 M | Orbimed Advisors, Llc | 2024-12-31 | 7.6 M |
Terns Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 306.41 M.Terns Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.24) | (0.26) | |
Return On Capital Employed | (0.29) | (0.31) | |
Return On Assets | (0.24) | (0.26) | |
Return On Equity | (0.26) | (0.27) |
Management Efficiency
Terns Pharmaceuticals has return on total asset (ROA) of (0.2013) % which means that it has lost $0.2013 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2956) %, meaning that it created substantial loss on money invested by shareholders. Terns Pharmaceuticals' management efficiency ratios could be used to measure how well Terns Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of March 2025, Return On Tangible Assets is likely to drop to -0.26. In addition to that, Return On Capital Employed is likely to drop to -0.31. As of the 25th of March 2025, Net Tangible Assets is likely to grow to about 334.4 M, while Total Assets are likely to drop about 203.2 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 4.35 | 3.18 | |
Tangible Book Value Per Share | 4.35 | 3.18 | |
Enterprise Value Over EBITDA | (2.75) | (2.89) | |
Price Book Value Ratio | 1.27 | 1.21 | |
Enterprise Value Multiple | (2.75) | (2.89) | |
Price Fair Value | 1.27 | 1.21 | |
Enterprise Value | 322.4 M | 338 M |
The strategic initiatives led by Terns Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Technical Drivers
As of the 25th of March, Terns Pharmaceuticals has the Variance of 16.61, coefficient of variation of (427.86), and Risk Adjusted Performance of (0.20). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Terns Pharmaceuticals, as well as the relationship between them.Terns Pharmaceuticals Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Terns Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Terns Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Terns Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Terns Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Terns Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Terns Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Terns Pharmaceuticals Outstanding Bonds
Terns Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Terns Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Terns bonds can be classified according to their maturity, which is the date when Terns Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
AerCap Global Aviation Corp BondUS00773HAA59 | View |
Terns Pharmaceuticals Predictive Daily Indicators
Terns Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Terns Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 59213.27 | |||
Daily Balance Of Power | (0.73) | |||
Rate Of Daily Change | 0.95 | |||
Day Median Price | 3.4 | |||
Day Typical Price | 3.37 | |||
Price Action Indicator | (0.18) | |||
Period Momentum Indicator | (0.19) |
Terns Pharmaceuticals Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 25th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 24th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 20th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
14th of February 2025 Other Reports | ViewVerify | |
11th of February 2025 Other Reports | ViewVerify | |
8K | 6th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
5th of February 2025 Other Reports | ViewVerify |
Terns Pharmaceuticals Forecast Models
Terns Pharmaceuticals' time-series forecasting models are one of many Terns Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Terns Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Terns Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Terns Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Terns shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Terns Pharmaceuticals. By using and applying Terns Stock analysis, traders can create a robust methodology for identifying Terns entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (44.68) | (46.92) | |
Operating Profit Margin | (44.87) | (47.12) | |
Net Loss | (45.14) | (47.40) | |
Gross Profit Margin | 0.44 | 0.39 |
Current Terns Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Terns analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Terns analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
19.06 | Strong Buy | 9 | Odds |
Most Terns analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Terns stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Terns Pharmaceuticals, talking to its executives and customers, or listening to Terns conference calls.
Terns Stock Analysis Indicators
Terns Pharmaceuticals stock analysis indicators help investors evaluate how Terns Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Terns Pharmaceuticals shares will generate the highest return on investment. By understating and applying Terns Pharmaceuticals stock analysis, traders can identify Terns Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 79.9 M | |
Common Stock Shares Outstanding | 79.5 M | |
Total Stockholder Equity | 345.9 M | |
Tax Provision | 260 K | |
Property Plant And Equipment Net | 1.5 M | |
Cash And Short Term Investments | 358.2 M | |
Cash | 161.4 M | |
Accounts Payable | 2.1 M | |
Net Debt | -160.1 M | |
50 Day M A | 4.0357 | |
Total Current Liabilities | 15.7 M | |
Non Current Assets Total | 1.8 M | |
Non Currrent Assets Other | 350 K | |
Stock Based Compensation | 15.6 M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.